

# Vaccine Manufacturing Taskforce

## Key messages



- Short term goal. There is an urgent need to find a way to create Xm doses of adenoviral vaccines and mRNA vaccines that are entering clinical trials in the UK.
- Long term goal. Important to determine how to create a UK capability that can deliver 25 million doses in 24 weeks by 2023.
- The industry-led vaccine manufacturing group has been working closely with Oxford University and Imperial College London, to assess supply chains and understand what they require to scale and rapidly deploy their vaccines.
- The UK has world leading science in academia, vaccines and advanced therapies, and with government funding, we can begin to create the capability to industrialise for health and economic benefits now, and in the future.
- The BIA led vaccine manufacturing taskforce was announced formally on Friday 17 April.
- The taskforce will consider any COVID-19 vaccines or therapies which emerge and will look to help where we can, regardless of whether the vaccine or therapy is UK or internationally based.
- The taskforce is now reporting directly into Sir Patrick Vallance, the Government's Chief Scientific Officer, where government is assessing what support it can provide to the taskforce.

#### **Oxford – Adenovirus Vaccine**

- A team at Oxford led by Dr Sandy Douglas, with Professor Sarah Gilbert and the CBF, successfully put in a bid to UKRI in partnership with BIA members Pall, Fujifilm, Cobra Biologics, Oxford Biomedica, Cell and Gene Therapy Catapult and VMIC to develop rapid scale up of such a vaccine to a 1M dose scale by this summer.
- Oxford began their human clinical trials on April 23<sup>rd</sup> 2020. Successful pre-clinical studies showing efficacy.
- £20m has been given by the Government for clinical trials.

#### **Imperial – mRNA vaccine**

- The taskforce is also supporting the work of Imperial College London, led by Professor Robin Shattock, where the team is focusing on an mRNA vaccine and where human clinical trials are expected to begin in the summer of 2020.
- Pre-clinical studies underway.
- £22.5m has been given by the Government for clinical trials

## **AstraZeneca**

- The University of Oxford has announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
- AstraZeneca will work with global partners on the international distribution of the vaccine, particularly working to make it available and accessible for low and medium income countries.

## **Medicines Manufacturing Industry Partnership (MMIP)**

- The work of the taskforce has come out of the work done by the Medicines Manufacturing Industry Partnership (MMIP). MMIP is continuously working to sustain the UK's leading position in medicines manufacturing technologies, including those related to advanced therapy medicinal products (ATMPs), continuous production and digitalisation.

## **BIA key messages**

- The BIA has networked the UK medicines manufacturing community and convened a COVID-19 taskforce within the UK who have the skills and capability to deliver the appropriate treatment. This taskforce is engaging with government and will support vaccine candidates reaching clinical trials scale and beyond.
- The BIA has been asked by the UK Government to co-ordinate capacity and ideas from our network to support the research, development and scale-up of the life sciences sector response to the pandemic.

## **Workstreams & leads**

Chair of the Vaccine Manufacturing Taskforce: Ian McCubbin, link to BEIS

1. Adenovirus vaccine: co-leads Peter Coleman, Cobra & Stephen Ward, CGT Catapult
2. mRNA vaccine manufacture and formulation: lead Dave Tudor, CPI
3. Antibody: Lead Dr Jane Osbourn, Alchemab and Paul Varley, VP, Biopharmaceutical Development at Kymab (Manufacturing lead)
4. Fill Finish: lead Ian Muir, Innovate UK
5. Supply Chain: lead Steve Bagshaw, Fujifilm
6. VMIC: lead, Matthew Duchars, VMIC
7. Communications: lead Pamela Tranter, UCL and Jack Fellows, BIA

## **Support Groups**

- MHRA – Ian Rees
- UKRI – Andy Jones
- GSK – Marc Jones
- KTN – Sarah Goulding

## **Spokespeople**

Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA)

Ian McCubbin OBE – Chair of the Vaccine Manufacturing Taskforce

Contact: – [jfellows@bioindustry.org](mailto:jfellows@bioindustry.org) or 07825942934